Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30

$0.68−0.07 (-8.81%)

Close on Nov 12, 2026Market cap $22.22MP/E –Yield –

Celularity profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Celularity's profit margin for the twelve months ending Jun 30, 2026 was -245.7%. For fiscal 2025 it was -345.4%, against -106.8% the year before. The highest annual figure on record is 79.0% in fiscal 2022.

Annual profit margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-345.4%	−238.7
FY2024	Dec 31, 2024	-106.8%	+755.3
FY2023	Dec 31, 2023	-862.0%	−941.0
FY2022	Dec 31, 2022	79.0%	+548.2
FY2021	Dec 31, 2021	-469.3%	+989.2
FY2020	Dec 31, 2020	-1458.4%	–

Quarterly profit margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2026	Jun 30, 2026	13.0%	+440.5
Q1 FY2026	Mar 31, 2026	22.7%	+195.6
Q4 FY2025	Dec 31, 2025	-593.6%	−520.3
Q3 FY2025	Sep 30, 2025	-436.7%	−263.5
Q2 FY2025	Jun 30, 2025	-427.5%	−374.0
Q1 FY2025	Mar 31, 2025	-172.9%	−22.9
Q4 FY2024	Dec 31, 2024	-73.3%	−152.1
Q3 FY2024	Sep 30, 2024	-173.2%	+2306.4
Q2 FY2024	Jun 30, 2024	-53.6%	+1578.5
Q1 FY2024	Mar 31, 2024	-149.9%	+1476.9
Q4 FY2023	Dec 31, 2023	78.8%	−512.9
Q3 FY2023	Sep 30, 2023	-2479.6%	−2595.6
Q2 FY2023	Jun 30, 2023	-1632.0%	−2898.6
Q1 FY2023	Mar 31, 2023	-1626.9%	−567.6
Q4 FY2022	Dec 31, 2022	591.8%	+675.0
Q3 FY2022	Sep 30, 2022	116.1%	−354.1
Q2 FY2022	Jun 30, 2022	1266.6%	+3283.4
Q1 FY2022	Mar 31, 2022	-1059.3%	+2006.1
Q4 FY2021	Dec 31, 2021	-83.2%	−203.8
Q3 FY2021	Sep 30, 2021	470.1%	+1850.9
Q2 FY2021	Jun 30, 2021	-2016.8%	–
Q1 FY2021	Mar 31, 2021	-3065.4%	–
Q4 FY2020	Dec 31, 2020	120.6%	–
Q3 FY2020	Sep 30, 2020	-1380.8%	–